A review of novel biomarkers and imaging techniques for assessing the severity of chemotherapy-induced peripheral neuropathy

References

• Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81(6):772–781.
   Google Scholar
• Shah A, Hoffman EM, Mauermann ML, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636–641.
   Google Scholar
• Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(Suppl 4):iv45–54.
   Google Scholar
• Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol. 2015;28(5):500–507.
   Google Scholar
• Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205–1211.
   Google Scholar
• Cavaletti G, Alberti P, Argyriou AA, et al. Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. J Peripher Nerv Syst. 2019;24(Suppl 2):S6–S12.
   Google Scholar
• Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–147.
   Google Scholar
• Briani C, Argyriou AA, Izquierdo C, et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19(4):299–306.
   Google Scholar
• Velasco R, Alberti P, Bruna J, et al. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S52–S62.
   Google Scholar
• Tamburin S, Park SB, Alberti P, et al. Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S40–S51.
   Google Scholar
• Islam B, Lustberg M, Staff NP, et al. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S63–S73.
   Google Scholar
• Staff NP, Cavaletti G, Islam B, et al. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S26–S39.
   Google Scholar
• Bjornard KL, Gilchrist LS, Inaba H, et al. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018;2(10):744–754.
   Google Scholar
• Liew WK, Pacak CA, Visyak N, et al. Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents. J Pediatr. 2016;178:227–232.
   Google Scholar
• Selvy M, Pereira B, Kerckhove N, et al. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. J Clin Med. 2020;9:8.
   Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book. 2015;e553–560. DOI:10.14694/EdBook_AM.2015.35.e553
   Google Scholar
• Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259(9):1936–1943.
   Google Scholar
• Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017;35(23):2604–2612. .
   Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967.
   Google Scholar
• Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncolo. 2020 Oct 1;38(28):3325–3348.
   Google Scholar
• Staff NP, Fehrenbacher JC, Caillaud M, et al. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2019;324:113121.
   Google Scholar
• Calls A, Carozzi V, Navarro X, et al. Pathogenesis of platinum-induced peripheral neurotoxicity: insights from preclinical studies. Exp Neurol. 2019;325:113141.
   Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479–494. .
   Google Scholar
• Argyriou AA, Park SB, Islam B, et al. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry 2019 jnnp-2019-320969 10.1136/jnnp-2019-320969
   Google Scholar
• Jacobs JM. Vascular permeability and neurotoxicity. Environ Health Perspect. 1978;26:107–116.
   Google Scholar
• Pettersson CA, Sharma HS, Olsson Y. Vascular permeability of spinal nerve roots. A study in the rat with Evans blue and lanthanum as tracers. Acta Neuropathol. 1990;81(2):148–154.
   Google Scholar
• Cavaletti G, Cavalletti E, Oggioni N, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology. 2000;21(3):389–393.
   Google Scholar
• Jimenez-Andrade JM, Herrera MB, Ghilardi JR, et al. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol Pain. 2008;4:10.
   Google Scholar
• Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2003;3(1):86–92.
   Google Scholar
• Kandula T, Farrar MA, Kiernan MC, et al. Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin Neurophysiol. 2017;128(7):1166–1175.
   Google Scholar
• Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005;146(7):1027–1039.
   Google Scholar
• Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009;27(8):1243–1249.
   Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–265.
   Google Scholar
• Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry. 1996;35(21):6806–6814.
   Google Scholar
• Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005;65(9):3828–3836.
   Google Scholar
• Argyriou AA, Cavaletti G, Bruna J, et al. Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol. 2014;88(9):1669–1679.
   Google Scholar
• Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000;123(Pt 12):2542–2551.
   Google Scholar
• Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry. 2008;79(11):1258–1261.
   Google Scholar
• Park SB, Alberti P, Kolb NA, et al. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019;24(Suppl 2):S13–S25.
   Google Scholar
• Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25(1):257–264.
   Google Scholar
• Dorsey SG, Kleckner IR, Barton D, et al. NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019 Jun 1;111(6):531–537.
   Google Scholar
• Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018;91(9):403–413.
   Google Scholar
• Haryani H, Fetzer SJ, Wu CL, et al. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncol Nurs Forum. 2017;44(3):E111–E123.
   Google Scholar
• Smith EML, Knoerl R, Yang JJ, et al. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials. Cancer Control. 2018;25(1):1073274818756608.
   Google Scholar
• Fuglsang-Frederiksen A, Pugdahl K. Current status on electrodiagnostic standards and guidelines in neuromuscular disorders. Clin Neurophysiol. 2011;122(3):440–455.
   Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335–2362.
   Google Scholar
• Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev Mol Diagn. 2003;3(5):525–529.
   Google Scholar
• Zhang A, Sun H, Wang P, et al. Recent and potential developments of biofluid analyses in metabolomics. J Proteomics. 2012;75(4):1079–1088.
   Google Scholar
• Karley D, Gupta D, Tiwari A. Biomarker for Cancer: A great Promise for Future. World J Oncol. 2011;2(4):151–157.
   Google Scholar
• Fornage BD. Peripheral nerves of the extremities: imaging with US. Radiology. 1988;167(1):179–182.
   Google Scholar
• Solbiati L, De Pra L, Ierace T, et al. High-resolution sonography of the recurrent laryngeal nerve: anatomic and pathologic considerations. AJR Am J Roentgenol. 1985;145(5):989–993.
   Google Scholar
• Suk JI, Walker FO, Cartwright MS. Ultrasonography of peripheral nerves. Curr Neurol Neurosci Rep. 2013;13(2):328.
   Google Scholar
• Suk JI, Sigur CM, Walker FO. Superficial fibular neuropathy: complementary role of ultrasound. Muscle Nerve. 2013;47(5):778.
   Google Scholar
• Silvestri E, Martinoli C, Derchi LE, et al. Echotexture of peripheral nerves: correlation between US and histologic findings and criteria to differentiate tendons. Radiology. 1995;197(1):291–296.
   Google Scholar
• Duncan I, Sullivan P, Lomas F. Sonography in the diagnosis of carpal tunnel syndrome. AJR Am J Roentgenol. 1999;173(3):681–684.
   Google Scholar
• Zaidman CM, Al-Lozi M, Pestronk A. Peripheral nerve size in normals and patients with polyneuropathy: an ultrasound study. Muscle Nerve. 2009;40(6):960–966.
   Google Scholar
• Zanette G, Fabrizi GM, Taioli F, et al. Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs. Clin Neurophysiol. 2018;129(11):2259–2267.
   Google Scholar
• Briani C, Campagnolo M, Lucchetta M, et al. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. Eur J Neurol. 2013;20(1):188–192.
   Google Scholar
• Pitarokoili K, Höffken N, Lönneker N, et al. Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. J Neuroimaging. 2019;29(1):133–139.
   Google Scholar
• Lycan TW, Hsu FC, Ahn CS, et al. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle Nerve. 2020;61(5):587–594.
   Google Scholar
• Chen Y, Haacke EM, Li J. Peripheral nerve magnetic resonance imaging. F1000Res. 2019;8:1803.
   Google Scholar
• Stewart JD. Peripheral nerve fascicles: anatomy and clinical relevance. Muscle Nerve. 2003;28(5):525–541.
   Google Scholar
• Howe FA, Filler AG, Bell BA, et al. Magnetic resonance neurography. Magn Reson Med. 1992;28(2):328–338.
   Google Scholar
• Filler AG, Howe FA, Hayes CE, et al. Magnetic resonance neurography. Lancet. 1993;341(8846):659–661.
   Google Scholar
• Chhabra A, Madhuranthakam AJ, Andreisek G. Magnetic resonance neurography: current perspectives and literature review. Eur Radiol. 2018;28(2):698–707.
   Google Scholar
• Trivedi JR, Phillips L, Chhabra A. Hereditary and acquired polyneuropathy conditions of the peripheral nerves: clinical considerations and MR neurography imaging. Semin Musculoskelet Radiol. 2015;19(2):130–136.
   Google Scholar
• Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.
   Google Scholar
• Gimber LH, Garland L, Krupinski EA, et al. Diffusion Tensor Imaging of the Ankle as a Possible Predictor of Chemotherapy Induced Peripheral Neuropathy: pilot Study. Curr Probl Diagn Radiol. 2019;48(2):121–126.
   Google Scholar
• Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60(5):877–878.
   Google Scholar
• Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand. 2004;109(3):188–193.
   Google Scholar
• Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008;119(11):2507–2512.
   Google Scholar
• Boland EG, Selvarajah D, Hunter M, et al. Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study. PLoS One. 2014;9(5):e96474.
   Google Scholar
• Hu L, Iannetti GD. Issues in Pain Prediction - Beyond Pain and Gain. Trends Neurosci. 2016;39(10):640–642.
   Google Scholar
• Hu L, Iannetti GD. Painful Issues in Pain Prediction. Trends Neurosci. 2016;39(4):212–220.
   Google Scholar
• Nudelman KN, McDonald BC, Wang Y, et al. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2016;34(7):677–683.
   Google Scholar
• Nudelman KN, Wang Y, McDonald BC, et al. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One. 2014;9(5):e96713.
   Google Scholar
• Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;1(2):189–195.
   Google Scholar
• Jayachandran D, Ramkrishna U, Skiles J, et al. Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression. CPT Pharmacometrics Syst Pharmacol. 2014;3:e110.
   Google Scholar
• Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12(12):1151–1161.
   Google Scholar
• Argyriou AA, Bruna J, Genazzani AA, et al. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017;13(8):492–504.
   Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589.
   Google Scholar
• Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518–e524.
   Google Scholar
• Meregalli C, Fumagalli G, Alberti P, et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol. 2018;307:129–132.
   Google Scholar
• Meregalli C, Fumagalli G, Alberti P, et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Arch Toxicol. 2020;94(7):2517–2522.
   Google Scholar
• Quattrini A, Previtali S, Feltri ML, et al. Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Glia. 1996;17(4):294–306.
   Google Scholar
• Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol. 2019;15(6):487–497.
   Google Scholar
• Sumitani M, Ogata T, Natori A, et al. Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. Biomed Rep. 2016;4(6):758–760.
   Google Scholar
• Azoulay D, Nasser R, Sharon R, et al. Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma. Br J Haematol. 2019;185(1):175–177.
   Google Scholar
• Azoulay D, Giryes S, Nasser R, et al. Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism. J Clin Neurol. 2019;15(4):511–516.
   Google Scholar
• Szudy-Szczyrek A, Mlak R, Bury-Kamińska M, et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol. 2020;191:77–89.
   Google Scholar
• Aloe L, Rocco ML, Bianchi P, et al. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10:239.
   Google Scholar
• Apfel SC, Arezzo JC, Lipson L, et al. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol. 1992;31(1):76–80.
   Google Scholar
• Aloe L, Manni L, Properzi F, et al. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci. 2000;86(1–2):84–93.
   Google Scholar
• De Santis S, Pace A, Bove L, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res. 2000;6(1):90–95.
   Google Scholar
• Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol. 2004;15(9):1439–1442. .
   Google Scholar
• Velasco R, Navarro X, Gil-Gil M, et al. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: prospective Clinical-Pathological Study. J Pain Symptom Manage. 2017;54(6):815–825.
   Google Scholar
• Wang XM, Lehky TJ, Brell JM, et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9.
   Google Scholar
• Meregalli C, Marjanovic I, Scali C, et al. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. J Neuroinflammation. 2018;15(1):232.
   Google Scholar
• Peters CM, Jimenez-Andrade JM, Jonas BM, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2007;203(1):42–54.
   Google Scholar
• Pizzamiglio C, Ripellino P, Prandi P, et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin. 2020;50(1):47–54. .
   Google Scholar
• Castello LM, Raineri D, Salmi L, et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm. 2017;4049098:2017.
   Google Scholar
• Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol. 2008;65(2):232–235.
   Google Scholar
• Clemente N, Raineri D, Cappellano G, et al. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. J Immunol Res. 2016;7675437:2016.
   Google Scholar
• Dianzani C, Bellavista E, Liepe J, et al. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci Rep. 2017;7:43718.
   Google Scholar
• Chen EI, Crew KD, Trivedi M, et al. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS One. 2015;10(12):e0145816.
   Google Scholar
• Verma P, Devaraj J, Skiles JL, et al. A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy. Sci Rep. 2020;10(1):9659.
   Google Scholar
• Apostolidis L, Schwarz D, Xia A, et al. Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy. PLoS One. 2017;12(8):e0183845.
   Google Scholar